Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Industry
Services-Medical Laboratories
Location
221 Crescent Street, Bldg. 17, Suite 401, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
MIRAGEN THERAPEUTICS, INC. (to 1/15/2021), SIGNAL GENETICS, INC. (to 2/10/2017), SIGNAL GENETICS LLC (to 7/9/2014)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.7K % +31.7%
Debt-to-equity 10.9 % +4.21%
Return On Equity -53.7 % -1.05%
Return On Assets -48.4 % -0.64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.8M shares +48.8%
Common Stock, Shares, Outstanding 63.8M shares +48.2%
Entity Public Float 1.02B USD +210%
Common Stock, Value, Issued 638K USD +48%
Weighted Average Number of Shares Outstanding, Basic 61.1M shares +44.6%
Weighted Average Number of Shares Outstanding, Diluted 61.1M shares +44.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 88.2M USD +81.3%
Operating Income (Loss) -238M USD -31.5%
Nonoperating Income (Expense) 19.7M USD +131%
Net Income (Loss) Attributable to Parent -218M USD -26.6%
Earnings Per Share, Basic -4.49 USD/shares +4.06%
Earnings Per Share, Diluted -4.49 USD/shares +4.06%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 613M USD +64%
Assets, Current 627M USD +63.8%
Property, Plant and Equipment, Net 1.53M USD -4.03%
Operating Lease, Right-of-Use Asset 1.48M USD +0.95%
Other Assets, Noncurrent 555K USD -43.5%
Assets 630M USD +63%
Accounts Payable, Current 2.68M USD -66%
Employee-related Liabilities, Current 7.06M USD +98.1%
Accrued Liabilities, Current 23.2M USD +8.1%
Contract with Customer, Liability, Current 288K USD 0%
Liabilities, Current 26.1M USD -11.7%
Contract with Customer, Liability, Noncurrent 500K USD -36.6%
Operating Lease, Liability, Noncurrent 900K USD -10%
Other Liabilities, Noncurrent 896K USD -13.8%
Liabilities 47.9M USD +32.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -367K USD -111%
Retained Earnings (Accumulated Deficit) -774M USD -39.2%
Stockholders' Equity Attributable to Parent 583M USD +66.2%
Liabilities and Equity 630M USD +63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.2M USD +27%
Net Cash Provided by (Used in) Financing Activities 177M USD +2058%
Net Cash Provided by (Used in) Investing Activities -143M USD -976%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 63.8M shares +48.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD +83.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 91.6M USD +3.53%
Interest Paid, Excluding Capitalized Interest, Operating Activities 452K USD +304%
Deferred Tax Assets, Valuation Allowance 156M USD +79.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 156M USD +79.7%
Operating Lease, Liability 1.63M USD +2.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -218M USD -27.2%
Lessee, Operating Lease, Liability, to be Paid 1.82M USD +2.94%
Property, Plant and Equipment, Gross 2.72M USD -18.3%
Operating Lease, Liability, Current 732K USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 474K USD +93.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 464K USD -38%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 191K USD +9.77%
Lessee, Operating Lease, Liability, to be Paid, Year Three 159K USD -30.9%
Deferred Tax Assets, Operating Loss Carryforwards 67.8M USD +47.3%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 159K USD -30.9%
Additional Paid in Capital 1.16B USD +49.9%
Depreciation, Depletion and Amortization 145K USD +38.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 64.6M USD +113%
Interest Expense 700K USD 0%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%